OBJECTIVES: To determine the prevalence, severity, and outcome associated with Clostridium difficile-associated disease (CDAD) acquired while in the cardiothoracic intensive care unit (CTICU). DESIGN: A 5-year retrospective study. SETTING: The CTICU. PARTICIPANTS: All CTICU patients with a positive C difficile stool toxin assay 48 hours after admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The results of all CTICU patients with a positive C difficile stool toxin assay were obtained from the Microbiology Department. Each patient's medical notes and charts then were reviewed in turn. A total of 27 of 5,199 (0.5%) CTICU patients acquired CDAD. The median age was 74 years (IQR 68-77), and 17 (63%) patients were male. There were 21 (78%) surgical patients; 13 (62%) were elective admissions. The most frequent diagnosis on admission was valvular heart disease (10 [37%] patients). Sixteen (59%) patients underwent coronary artery bypass graft (CABG) surgery and/or valvular heart surgery. The median interval between CTICU admission and CDAD diagnosis was 10 days (IQR 5-18). Previously identified risk factors for ICU-acquired CDAD included age >65 years (23), antibiotic use (26), and medical device requirements (27). At the time of diagnosis, 14 (52%) patients had moderate CDAD. After treatment initiation, 8 (30%) patients developed worsening CDAD. The 30-day in-hospital mortality rate for CTICU-acquired CDAD was 26% (7 patients). CONCLUSIONS: C difficile-associated disease rarely is acquired in the CTICU. Approximately one third of patients may experience disease progression, and just over a quarter may die within 30 days of diagnosis. The implementation of recommended severity definitions and treatment algorithms may reduce complication rates and merits prospective evaluation.
OBJECTIVES: To determine the prevalence, severity, and outcome associated with Clostridium difficile-associated disease (CDAD) acquired while in the cardiothoracic intensive care unit (CTICU). DESIGN: A 5-year retrospective study. SETTING: The CTICU. PARTICIPANTS: All CTICUpatients with a positive C difficile stool toxin assay 48 hours after admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The results of all CTICUpatients with a positive C difficile stool toxin assay were obtained from the Microbiology Department. Each patient's medical notes and charts then were reviewed in turn. A total of 27 of 5,199 (0.5%) CTICUpatients acquired CDAD. The median age was 74 years (IQR 68-77), and 17 (63%) patients were male. There were 21 (78%) surgical patients; 13 (62%) were elective admissions. The most frequent diagnosis on admission was valvular heart disease (10 [37%] patients). Sixteen (59%) patients underwent coronary artery bypass graft (CABG) surgery and/or valvular heart surgery. The median interval between CTICU admission and CDAD diagnosis was 10 days (IQR 5-18). Previously identified risk factors for ICU-acquired CDAD included age >65 years (23), antibiotic use (26), and medical device requirements (27). At the time of diagnosis, 14 (52%) patients had moderate CDAD. After treatment initiation, 8 (30%) patients developed worsening CDAD. The 30-day in-hospital mortality rate for CTICU-acquired CDAD was 26% (7 patients). CONCLUSIONS: C difficile-associated disease rarely is acquired in the CTICU. Approximately one third of patients may experience disease progression, and just over a quarter may die within 30 days of diagnosis. The implementation of recommended severity definitions and treatment algorithms may reduce complication rates and merits prospective evaluation.
Authors: L Sabau; A Meybeck; J Gois; P Devos; P Patoz; N Boussekey; P-Y Delannoy; A Chiche; H Georges; O Leroy Journal: Infection Date: 2013-06-19 Impact factor: 3.553
Authors: Brian T Bateman; Jeremy A Rassen; Sebastian Schneeweiss; Katsiaryna Bykov; Jessica Myers Franklin; Joshua J Gagne; Jennifer M Polinski; Jun Liu; Alexander Kulik; Michael A Fischer; Niteesh K Choudhry Journal: J Thorac Cardiovasc Surg Date: 2013-03-28 Impact factor: 5.209
Authors: David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg Journal: Am J Gastroenterol Date: 2016-08-30 Impact factor: 10.864
Authors: Katherine A Kirkwood; Brian C Gulack; Alexander Iribarne; Michael E Bowdish; Giampaolo Greco; Mary Lou Mayer; Karen O'Sullivan; Annetine C Gelijns; Nishit Fumakia; Ravi K Ghanta; Jesse M Raiten; Anuradha Lala; Joseph S Ladowski; Eugene H Blackstone; Michael K Parides; Alan J Moskowitz; Keith A Horvath Journal: J Thorac Cardiovasc Surg Date: 2017-09-28 Impact factor: 5.209
Authors: J Czepiel; J Kędzierska; G Biesiada; M Birczyńska; W Perucki; P Nowak; A Garlicki Journal: Epidemiol Infect Date: 2015-04-10 Impact factor: 4.434
Authors: Styliani Karanika; Suresh Paudel; Fainareti N Zervou; Christos Grigoras; Ioannis M Zacharioudakis; Eleftherios Mylonakis Journal: Open Forum Infect Dis Date: 2015-12-01 Impact factor: 3.835